Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - July 2013


Pharmaceutical Sales & Brand Management Conference

08 Jul 2013 - 09 Jul 2013 - Las Vegas, NV , USA



Bookmark and Share


How does the pharmaceutical salesperson of the future delivery value?

The answer is no longer simple. What was once a standard operating procedure has been thrown into flux. The market is in the midst of a sea change and pharmaceutical companies are now re-evaluating brand & life cycle management, sales team design & incentives, physician & payer relationships and social media campaigns. Decisions made on these strategic issues will have a direct impact on the organization’s ability to grow as a brand.

However significant change brings new opportunity. The best strategic plans will chart new courses and create new market leaders. Sales teams of the future will solidify new bonds with customers driving brand value. New marketing campaigns will harness the voice of the customer to enhance public awareness. Access will be created by satisfying needs. But only those who understand this dynamic market and develop the best strategic tools will enjoy the successes this new future holds.

GTC’s Pharmaceutical Sales & Brand Management Conference assembles key strategic leaders to discuss and bring clarity to a transitioning market. They will discuss issues, including:
  
  · Incentivizing sales teams
  · Selling to managed care systems
  · Healthcare reform
  · Market access
  · Social media campaigns
  · Managing specialty drugs
  · Biologic strategies
  · ACOs and their relationships with pharma

This is a unique opportunity to hear from and network with your peers in an exclusive setting devoted entirely to pharmaceutical sales, marketing and brand management.


2013 Pharmaceutical Sales & Brand Management Conference Committee

Conference Advisory Board Members:
Dan Brennan, Vice President, Neurology,
 Lundbeck
Dan Camardo, Senior Director, Marketing Operations,
 Astellas Pharma US
Frank Dolan, Director, Synergy Sales Force,
 Amylin Pharmaceuticals
Christine Fiore, Compliance Business Partner, Commercial Compliance,
 Boehring Ingelheim
John Grano, Vice President, Global Sales & Marketing Effectiveness,
 Sanofi Pasteur
Kari K. Loeser, Compliance Counsel,
 Jazz Pharmaceuticals
Tom McCann, Vice President, Oncology Sales and Marketing,
 Accredo, a Division of Express Scripts

We look forward to seeing you at the conference!
 



Further information
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!